At Vaxil, we believe that collaborating with academic institutions, hospitals and BioPharma companies will increase our knowledge and boost our business.

Using our VaxHit technology, we have indentified a large number of vaccine candidates with a potential role in the treatment of cancer and key intracellular pathogens in particular Mtb, Malaria, Toxoplasma, CMV, EBV, HIV, HCV and Influenza. This pipeline offers numerous opportunities. Academic groups reviewed and approved by Vaxil are welcome to use our products in their own models for non-commercial applications.

We are also actively seeking joint development and licensing opportunities for our products by pharmaceutical and biotech companies, which are active in the field of vaccines and immunotherapy.

Vaxil is pleased to announce that it has signed partnership agreements with:

- Hadassah Medical Center, Jerusalem, Israel (ImMucin)
- Rambam Medical Center, Haifa, Israel (ImMucin)
- Tel-Aviv University, Tel-Aviv, Israel (ImMucin, mTbuVax)
- USC, santiago de compostela, Spain (mTbuVax)
- Harvard, Boston, USA (ImMucin)
- Bar-Ilan University, Ramat-Gan, Israel (VaxHit)
- Maccabi Health Organization, Rehovot, Israel (mTbuVax)
- Kaplan Medical Center, Rehovot, Israel (mTbuVax)
- Immunovaccine (TSX-V:IMV), Halifax, Canada (Undisclosed)